Your browser doesn't support javascript.
Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein.
Zhou, Yong-Fei; Nie, Jiao-Jiao; Shi, Chao; Ning, Ke; Cao, Yu-Feng; Xie, Yanbo; Xiang, Hongyu; Xie, Qiuhong.
  • Zhou YF; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
  • Nie JJ; School of Life Sciences, Jilin University, Changchun 130012, P.R. China.
  • Shi C; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
  • Ning K; School of Life Sciences, Jilin University, Changchun 130012, P.R. China.
  • Cao YF; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
  • Xie Y; School of Life Sciences, Jilin University, Changchun 130012, P.R. China.
  • Xiang H; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
  • Xie Q; School of Life Sciences, Jilin University, Changchun 130012, P.R. China.
J Microbiol Biotechnol ; 32(10): 1335-1343, 2022 Oct 28.
Article in English | MEDLINE | ID: covidwho-2115579
ABSTRACT
COVID-19 is an emerging disease that poses a severe threat to global public health. As such, there is an urgent demand for vaccines against SARS-CoV-2, the virus that causes COVID-19. Here, we describe a virus-like nanoparticle candidate vaccine against SARS-CoV-2 produced by an E. coli expression system. The fusion protein of a truncated ORF2-encoded protein of aa 439~608 (p170) from hepatitis E virus CCJD-517 and the receptor-binding domain of the spike protein from SARS-CoV-2 were expressed, purified and characterized. The antigenicity and immunogenicity of p170-RBD were evaluated in vitro and in Kunming mice. Our investigation revealed that p170-RBD self-assembled into approximately 24 nm virus-like particles, which could bind to serum from vaccinated people (p < 0.001) and receptors on cells. Immunization with p170-RBD induced the titer of IgG antibody vaccine increased from 14 days post-immunization and was significantly enhanced after a booster immunization at 28 dpi, ultimately reaching a peak level on 42 dpi with a titer of 4.97 log10. Pseudovirus neutralization tests showed that the candidate vaccine induced a strong neutralizing antibody response in mice. In this research, we demonstrated that p170-RBD possesses strong antigenicity and immunogenicity and could be a potential candidate for use in future SARS-CoV-2 vaccine development.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Hepatitis E virus / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Animals / Humans Language: English Journal: J Microbiol Biotechnol Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Hepatitis E virus / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Animals / Humans Language: English Journal: J Microbiol Biotechnol Year: 2022 Document Type: Article